radiation therapy for prostate cancer

From Aaushi
Jump to navigation Jump to search

Indications

Management

More general terms

References

  1. 1.0 1.1 1.2 1.3 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15 16, 17, 18. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015, 2018.
  2. 2.0 2.1 Thompson IM JR et al, Adjuvant radiotherapy for pathologically advanced prostate cancer. A randomized clinical trial. JAMA 2006, 296:2329 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17105795
  3. 3.0 3.1 Van der Kwast TH et al, Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911 J Clin Oncol 2007, 25:4178
  4. 4.0 4.1 Wiegel T et al Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009 Jun 20; 27:2924. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19433689
  5. 5.0 5.1 Denham JW Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial The Lancet Oncology, 25 March 2011 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21440505 <Internet> http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70063-8/fulltext
    Parker C Androgen deprivation before prostate radiotherapy: how long is long enough? The Lancet Oncology, 25 March 2011 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21440506 <Internet> http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70072-9/fulltext
  6. 6.0 6.1 Bolla M et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012 Oct 19; PMID: https://www.ncbi.nlm.nih.gov/pubmed/23084481
  7. 7.0 7.1 Basch E et al Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol. Sept 8, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25199761 <Internet> http://jco.ascopubs.org/content/early/2014/09/03/JCO.2013.54.8404.full.pdf+html
  8. 8.0 8.1 Wallis CJ et al Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 2016;352:i851 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26936410 <Internet> http://www.bmj.com/content/352/bmj.i851 Eyler CE, Zietman AL A (relatively) risky business: the link between prostatic radiotherapy and second malignancies. BMJ 2016;352:i1073 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26935234 <Internet> http://www.bmj.com/content/352/bmj.i1073
  9. 9.0 9.1 Terrisse S, Karamouza E, Parker CC et al Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes. A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. JAMA Oncol. Published online December 12, 2019. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31830233 https://jamanetwork.com/journals/jamaoncology/fullarticle/2757384